Startup Veracyte Presents Data, Prepares to Launch Thyroid MDx Test | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – On the heels of data from a clinical validation study indicating its thyroid cancer test can classify fine needle aspirates as benign with high accuracy, Veracyte said this week it is on schedule to initiate commercialization of the test later this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.